Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 05/19/2011
Langenhuijsen JF et al. – Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with androgen deprivation therapy (ADT). Patients with low PSA nadir do significantly worse with IAD compared with CAD. Low testosterone after ADT and incomplete testosterone recovery may explain similar quality of life (QOL). IAD is not a good treatment option for many metastatic prostate cancer patients.